Senior Analyst
- Marco.Boorsma@forbion.com
- Download vCard 
With over 10 years of experience in the biotechnology industry Marco joined Forbion Capital Partners in 2007 as Senior Analyst. In his role he is responsible for scouting and analyzing new investment opportunities, market and trend analysis to support Forbion’s business strategy, and generating opinion reports on investment focus areas.
Prior to joining Forbion Marco was business development director at DSM Pharmaceutical Products, the chemicals and biologicals contract manufacturing division of Royal DSM. At DSM he was responsible for negotiating and securing new contract manufacturing projects and out-licensing of biomanufacturing technology to the pharmaceutical and biotechnology industry. Before entering into the business development role Marco was project manager and scientist responsible for process development and cGMP manufacturing of biopharmaceuticals. His in-depth knowledge of (contract) production is now a valuable asset to Forbion’s portfolio companies.
After obtaining a master’s degree in molecular biology from the University of Groningen, Marco received his PhD in biotechnology from the ‘Eidgenössische Technische Hochschule’ (ETH) in Zürich, Switzerland for his work on virus-based gene expression systems. Marco executed his work in the groups of Prof. James Bailey and Prof. Ari Helenius at the ETH, and at the Laboratory of Molecular Biology of the Medical Research Counsel in Cambridge, UK. Marco developed several cell lines and processes for high-value biosimilar proteins while working at Cytos Biotechnology, an ETH-spin out and now a publicly traded vaccine development company.
